RahulAggarwalMD

Oncology • San Francisco, CA

Assistant Professor of Hematology/Oncology, Director of STAND Clinic, UCSF

Join to view full profile

Dr. Aggarwal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aggarwal's full profile

Already have an account?

Office
505 Parnassus Ave
Room M987
San Francisco, CA 94143
Phone+1 415-476-1000

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2010 - 2013
University of California (San Francisco)Residency, Internal Medicine, 2006 - 2009
Northwestern University The Feinberg School of MedicineClass of 2006

Certifications & Licensure

CA State Medical License 2008 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 1
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer Start of enrollment: 2013 Oct 29
Completed
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer Start of enrollment: 2014 Jun 16
Terminated
Phase 2
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2014 Sep 02
Terminated
Phase 2
MRI With C13 Pilot Study Prostate Cancer Start of enrollment: 2016 Oct 12
Terminated
Early Phase 1
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC Start of enrollment: 2015 Nov 20
Completed
Phase 1, Phase 2
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer Start of enrollment: 2016 Mar 22
Recruiting
Early Phase 1
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. Start of enrollment: 2019 Feb 12
Active, not recruiting
Phase 1, Phase 2
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2021 Sep 28
Active, not recruiting
Phase 2
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) Start of enrollment: 2018 Jul 17
Recruiting
Phase 3
Roles: Contact, Study Chair
Join now to see all

Publications & Presentations

PubMed

5 citations
Initial Experience withGa-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
Vadim S Koshkin, Vipul Kumar, Brad Kline, Domenique Escobar, Maya Aslam
Journal of Nuclear Medicine. 2024-02-01
41 citations
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer
Yang Su, Yue Liu, Christopher R. Behrens, Scott Bidlingmaier, Nam-Kyung Lee
JCI Insight. 2018-09-06
248 citations
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
Aaron R. Hansen, Christophe Massard, Patrick A. Ott, Naomi B. Haas, Juanita Lopez
Annals of Oncology. 2018-08-01

Lectures

Exceptional responders to abexinostat (ABX) plus pazopanib (PAZ) in pretreated renal cell carcinoma (RCC) and other solid tumors: Long-term follow-up of a phase 1b study.
2019 ASCO Annual Meeting - 6/1/2019
DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant pr...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Breaking the Boundaries Between Radiology and Oncology: GU Oncology Profiles Thomas a. Hope, MDApril 28th, 2022
Androgen Deprivation Therapy and SARS-CoV-2 in Men with Prostate Cancer: Findings from the University of California Health System RegistryFebruary 8th, 2021
Xynomic Pharma to Present Long-Term Follow up Data Showing Abexinostat, Combined with Pazopanib, Has Durable Responses in Patients with Pre-Treated Kidney CancerMay 21st, 2019
Join now to see all